Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27811000 | 0.99 | AGER (0.52) | AGERMTNR1AHSD11B1L3MBTL1MEN1 | |
| SCHEMBL9001746 | 0.94 | HSD11B1 (0.54) | AGERMTNR1AHSD11B1L3MBTL1MEN1 | |
| SCHEMBL13911269 | 0.88 | AGER (0.56) | AGERMTNR1AHSD11B1L3MBTL1MEN1 | |
| SCHEMBL13911241 | 0.88 | SLC6A4 (0.56) | AGERMTNR1AHSD11B1L3MBTL1MEN1 | |
| SCHEMBL10721820 | 0.87 | HSD11B1 (0.57) | AGERMTNR1AHSD11B1SLC6A4KCNH2 | |
| SCHEMBL10722289 | 0.84 | HSD11B1 (0.56) | AGERMTNR1AHSD11B1L3MBTL1MEN1 | |
| SCHEMBL15285371 | 0.84 | AGER (0.52) | AGERMTNR1AL3MBTL1MEN1KMT2A | |
| SCHEMBL9543490 | 0.84 | MEN1 (0.51) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL13434159 | 0.83 | SLC6A4 (0.58) | AGERMTNR1AHSD11B1MEN1KMT2A | |
| SCHEMBL4139952 | 0.82 | L3MBTL1 (0.62) | AGERMTNR1AHSD11B1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514431-B2 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060173013-A1 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173013-A1 | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity | CCR2, CCR1, CCRL2 | AGER 1997/4885MTNR1A 317/4885HSD11B1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.